Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Roivant Sciences in a research note issued on Wednesday, April 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.25) for the quarter, down from their prior forecast of ($0.23). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Roivant Sciences' current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Roivant Sciences' Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.49) EPS.
A number of other research analysts have also weighed in on the stock. The Goldman Sachs Group raised their target price on shares of Roivant Sciences from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday. Bank of America lifted their price target on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a "neutral" rating in a research report on Tuesday, January 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Wednesday. Wolfe Research began coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They set an "outperform" rating and a $17.00 price target on the stock. Finally, Piper Sandler began coverage on Roivant Sciences in a research report on Friday, January 5th. They issued an "overweight" rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $16.90.
Check Out Our Latest Stock Report on ROIV
Roivant Sciences Price Performance
ROIV stock traded up $0.23 during trading on Friday, hitting $11.74. The stock had a trading volume of 5,855,017 shares, compared to its average volume of 7,242,943. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. Roivant Sciences has a twelve month low of $7.01 and a twelve month high of $13.24. The stock has a market capitalization of $9.46 billion, a P/E ratio of 2.26 and a beta of 1.34. The company's 50-day moving average price is $10.82 and its two-hundred day moving average price is $10.37.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The company had revenue of $37.14 million for the quarter, compared to analysts' expectations of $30.72 million.
Hedge Funds Weigh In On Roivant Sciences
Institutional investors have recently modified their holdings of the business. Dagco Inc. acquired a new position in shares of Roivant Sciences during the fourth quarter worth $27,000. FNY Investment Advisers LLC acquired a new position in shares of Roivant Sciences during the fourth quarter worth $33,000. Headlands Technologies LLC acquired a new position in shares of Roivant Sciences during the fourth quarter worth $36,000. Allspring Global Investments Holdings LLC purchased a new stake in Roivant Sciences in the third quarter valued at $44,000. Finally, Royal Bank of Canada lifted its position in Roivant Sciences by 2,333.5% in the second quarter. Royal Bank of Canada now owns 4,210 shares of the company's stock valued at $43,000 after acquiring an additional 4,037 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Insiders Place Their Bets
In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the business's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the transaction, the chief operating officer now owns 532,207 shares in the company, valued at $5,811,700.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.60% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
